

<b>NCT ID</b>	NCT05743036
<b>Title</b>	ZN-c3 in Adult Participants With BRAF mutant Metastatic Colorectal Cancer
<b>Phase</b>	Phase 1
<b>Date Added</b>	2023-02-24
<b>Location</b>	California, United States Kansas, United States Texas, United States Australia Germany Hungary Italy Poland Spain
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Terminated
<b>Drugs</b>	cetuximab, encorafenib, ZN-c3
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT05759728
<b>Title</b>	A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2023-03-08
<b>Location</b>	Australia
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT05714553
<b>Title</b>	NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2023-02-06
<b>Location</b>	United Kingdom
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Terminated
<b>Drugs</b>	Docetaxel, Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab
<b>Tags</b>	MSI-H/ MMRd
<b>NCT ID</b>	NCT05426005
<b>Title</b>	Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2022-06-21
<b>Location</b>	China
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Cadonilimab
<b>Tags</b>	MSI-H/ MMRd

<b>NCT ID</b>	NCT05653882
<b>Title</b>	A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
<b>Phase</b>	Phase 1
<b>Date Added</b>	2022-12-16
<b>Location</b>	California, United States Connecticut, United States Florida, United States Illinois, United States Massachusetts, United States Michigan, United States Missouri, United States New Jersey, United States New York, United States North Carolina, United States Oregon, United States Tennessee, United States Utah, United States Virginia, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT05464030
<b>Title</b>	Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
<b>Phase</b>	Phase 1
<b>Date Added</b>	2022-07-19
<b>Location</b>	California, United States Rhode Island, United States Texas, United States Canada Japan South Korea Spain
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	M9140
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT05198934
<b>Title</b>	Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (CodeBreak 300)
<b>Phase</b>	Phase 3
<b>Date Added</b>	2022-01-20

<b>Location</b>	Alabama, United States California, United States District of Columbia, United States Florida, United States Georgia, United States Michigan, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Australia France Germany Greece Italy Japan Mexico South Korea Spain Taiwan United Kingdom
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT05349890
<b>Title</b>	Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
<b>Phase</b>	Phase 1
<b>Date Added</b>	2022-04-27
<b>Location</b>	Oregon, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	CDX-1140, Pembrolizumab, Keytruda
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT05350917
<b>Title</b>	Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy
<b>Phase</b>	Phase 2
<b>Date Added</b>	2022-04-28
<b>Location</b>	
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Not yet recruiting
<b>Drugs</b>	Tislelizumab
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT05409417
<b>Title</b>	Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status
<b>Phase</b>	Phase 2
<b>Date Added</b>	2022-06-08

Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Unknown status
Drugs	Bevacizumab, cetuximab, FOLFOX, Tislelizumab, XELOX
Tags	MSS/ MMRp